home / stock / bctx / bctx quote
Last: | $2.205 |
---|---|
Change Percent: | 2.08% |
Open: | $2.13 |
Close: | $2.16 |
High: | $2.35 |
Low: | $2.13 |
Volume: | 3,218 |
Last Trade Date Time: | 04/18/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.205 | $2.13 | $2.16 | $2.35 | $2.13 | 3,218 | 04-18-2024 |
$2.16 | $2.32 | $2.16 | $2.32 | $2.1001 | 26,237 | 04-17-2024 |
$2.28 | $2.28 | $2.28 | $2.34 | $2.02 | 141,623 | 04-16-2024 |
$2.32 | $2.45 | $2.32 | $2.56 | $2.3 | 35,551 | 04-15-2024 |
$2.49 | $2.71 | $2.49 | $2.8499 | $2.47 | 116,630 | 04-12-2024 |
$2.68 | $2.75 | $2.68 | $2.82 | $2.6401 | 24,928 | 04-11-2024 |
$2.73 | $2.79 | $2.73 | $2.84 | $2.6798 | 86,241 | 04-10-2024 |
$2.8501 | $2.88 | $2.8501 | $2.95 | $2.84 | 33,295 | 04-09-2024 |
$2.93 | $2.72 | $2.93 | $2.9432 | $2.69 | 37,120 | 04-08-2024 |
$2.72 | $2.8 | $2.72 | $2.925 | $2.7 | 35,352 | 04-05-2024 |
$2.79 | $2.88 | $2.79 | $3.03 | $2.76 | 98,964 | 04-04-2024 |
$2.88 | $2.77 | $2.88 | $3.01 | $2.7659 | 93,059 | 04-03-2024 |
$2.75 | $2.83 | $2.75 | $2.85 | $2.71 | 23,063 | 04-02-2024 |
$2.83 | $2.86 | $2.83 | $2.89 | $2.76 | 41,604 | 04-01-2024 |
$2.86 | $2.64 | $2.86 | $2.94 | $2.6001 | 87,185 | 03-29-2024 |
$2.86 | $2.64 | $2.86 | $2.94 | $2.6001 | 87,185 | 03-28-2024 |
$2.67 | $2.6 | $2.67 | $2.68 | $2.49 | 85,183 | 03-27-2024 |
$2.54 | $2.8 | $2.54 | $2.82 | $2.4006 | 146,432 | 03-26-2024 |
$2.85 | $2.65 | $2.85 | $2.92 | $2.6068 | 190,437 | 03-25-2024 |
$2.52 | $2.35 | $2.52 | $2.52 | $2.21 | 138,875 | 03-22-2024 |
News, Short Squeeze, Breakout and More Instantly...
BriaCell Therapeutics Corp. Company Name:
BCTX Stock Symbol:
NASDAQ Market:
Preclinical data shows that BriaCell’s Bria-OTS+™ and Bria-PROS+™ effectively induce an anti-cancer immune response via multiple mechanisms including naïve helper and killer T cells, dendritic cells, and natural killer (NK) cells The novel mechanisms of actio...
PFS of 4.2 months in Phase 2 ADC resistant patients receiving Bria-IMT™ pivotal Phase 3 formulation is twice that of controls in similar studies PFS results reinforced by larger number of prior treatments in Bria-IMT™ population than in comparable studies Bri...